Kronos Bio (Kronos Bio) Additional Paid-In Capital : $675.78 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Additional Paid-In Capital?

Kronos Bio's quarterly additional paid-in capital increased from Sep. 2023 ($662.36 Mil) to Dec. 2023 ($667.86 Mil) and increased from Dec. 2023 ($667.86 Mil) to Mar. 2024 ($675.78 Mil).

Kronos Bio's annual additional paid-in capital increased from Dec. 2021 ($608.06 Mil) to Dec. 2022 ($641.42 Mil) and increased from Dec. 2022 ($641.42 Mil) to Dec. 2023 ($667.86 Mil).

Kronos Bio Additional Paid-In Capital Historical Data

The historical data trend for Kronos Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Additional Paid-In Capital Chart

Kronos Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

0.27

577.39

608.06

641.42

667.86

Kronos Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															648.33	655.92	662.36	667.86	675.78

Kronos Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kronos Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kronos Bio (Kronos Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402

Website

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Executives

Jorge Dimartino	officer: Chief Medical Officer & VP	C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore	officer: Chief Scientific Officer	C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz	officer: COO & General Counsel	3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger	director, 10 percent owner, officer: President & CEO	333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner	officer: Interim CFO	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130